Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826136 | 0.89 | MAPT (0.38) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL16122437 | 0.85 | GRIA4 (0.39) | ADORA1ADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL21972995 | 0.77 | ALDH1A1 (0.43) | ADORA1ADORA2AMEN1KMT2AGRIA2 | |
| SCHEMBL24329069 | 0.76 | ADORA1 (0.48) | ADORA1ADORA2A | |
| SCHEMBL18137884 | 0.76 | ADORA1 (0.37) | ADORA1ADORA2AGRIA2GRIA4ADRA2A | |
| SCHEMBL13826028 | 0.75 | MAPT (0.43) | ADORA1ADORA2AMEN1KMT2AHTT | |
| SCHEMBL17546162 | 0.75 | CYP11B1 (0.44) | ADORA1ADORA2ACYP11B1CYP11B2HTT | |
| SCHEMBL16122084 | 0.75 | CYP11B1 (0.44) | ADORA1ADORA2ACYP11B1CYP11B2MEN1 | |
| SCHEMBL13826009 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AHTTHSD17B10KDM4E | |
| SCHEMBL18135408 | 0.74 | ADORA1 (0.36) | ADORA1ADORA2AGRIA2GRIA4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056027-A1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2022-02-24 | — | — | US | claimed |
| EP-3899004-A2 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | Astrazeneca AB (SE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127208-A2 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2020-06-25 | — | — | WO | claimed |
| US-12365678-B2 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl) cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates | ASTRAZENECA AB (SE) | 2025-07-22 | — | — | US | disclosed |
| US-20220056027-A1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2022-02-24 | — | — | US | disclosed |
| US-20220056027-A1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2022-02-24 | — | — | US | disclosed |
| EP-3899004-A2 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | Astrazeneca AB (SE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127208-A2 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127208-A2 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365678-B2 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl) cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates | TPMT, CYP3A7, HTR7 | ADORA1 725/4885ADORA2A 632/4885ADORA2B 239/4885 |
| US-20220056027-A1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | CYP3A7, UGT2B7, CDK7 | ADORA1 1128/4885ADORA2A 607/4885ADORA2B 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.